IP22: Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I
Friday, May 15, 2026 3:30 PM to 5:30 PM · 2 hr. (America/New_York)
146C
Poster and Podium Sessions
Sexual Function
Friday, May 15
IP22-01: ANDROGEN RECEPTOR POLYMORPHISM MAY DETERMINE HYPOGONADISM SEVERITY AND TRT RESPONSE
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-02: Long-Term Adherence and Switching Patterns Across Testosterone Formulations: A Real-World Analysis of Nearly 50,000 Men
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-03: Contemporary testosterone therapy prescribing patterns spanning over two decades: what is the impact of FDA label changes and new oral formulations?
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-04: Obesity, Not PDE5 Inhibition, Drives Uric Acid Levels in Men with Erectile Dysfunction: A Retrospective Study
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-05: Enclomiphene Provides Hormonal Outcomes Comparable to Clomiphene in Men with Hypogonadism
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-06: Clomiphene Citrate Therapy and Lipid Profile Changes in Men with Hypogonadism: Findings from an Expanded Cohort
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-07: Low Testosterone as a Risk Factor for Early Inflatable Penile Prosthesis Failure
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-08: Symptom Improvement Differs by Testosterone Therapy Modality in Men with Hypogonadism: A Real-World Cohort Analysis
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-09: Propensity-Matched Analysis of Human Chorionic Gonadotropin Adjunctive Therapy in Testosterone Replacement: Impact on Patient-Reported Outcomes
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-10: TREATMENT AND COST PREFERENCES FOR FEMALE SEXUAL DYSFUNCTION: ANALYSIS FROM A SURVEY OF 934 WOMEN
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-11: Genitourinary Syndrome of Lactation: Patient-Reported Survey of Symptom Burden, Care Gaps, and Treatment Utilization in the Postpartum Period
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-12: GLP-1 Receptor Agonists Associated with Reduce Pelvic Complications in Postpartum Women: A Global Real-World Matched Cohort Study
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-13: Sexual Function and Stimulation Beyond the Clitoris in Women with FGM/C: A Systematic Review of Alternative Pathways and Urogenital Anatomy
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-14: Beyond nerve-sparing: Low-intensity Extracorporeal Shockwave Therapy boosts erectile recovery after Robot-Assisted Radical Prostatectomy
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
Riccardo Mastroianni · IRCCS "Regina Elena" National Cancer Institute
IP22-15: Low-Intensity Extracorporeal Shock Wave Therapy for Erectile Dysfunction: A Comprehensive Systematic review and Meta-Analysis
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-16: Electrohydraulic low-intensity shockwave therapy for vasculogenic erectile dysfunction: first results from the PRIAPUS phase IV trial
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-17: Low-intensity Extracorporeal Shockwave Therapy on penile rehabilitation after nerve sparing Robot-Assisted Radical Prostatectomy: preliminary results from a Randomized Controlled Trial
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
Riccardo Mastroianni · IRCCS "Regina Elena" National Cancer Institute
IP22-18: Does Veno-Occlusive Dysfunction on Penile Vascular Ultrasound Truly Correlate with Erectile Function?
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-19: Evaluating Mental Health Risk and Psychiatric Care Access in Young Men with Erectile Dysfunction
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-20: The Intracavernosal Injection Therapy Checklist: A Means of Identifying Problem Patients
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-21: Treatment with Sildenafil oral film improves orgasmic intensity as measured by the Orgasmometer: results of a placebo-controlled trial
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-22: Exploring Utilization and Satisfaction with Vacuum Erection Devices (VED) Among Men Experiencing Erectile Dysfunction (ED) Or Peyronie’s Disease (PD)
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-23: Spermatic cord block as a treatment modality in chronic scrotal pain: a tertiary referral center study
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-24: Prostate Specific Antigen Declines in a Subset of Men Started on Testosterone-Replacement Therapy
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-25: PDE5 Inhibitors and Cardiovascular Outcomes in Men with ED: Propensity-Weighted Hazard Ratios over 12 Months
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-26: Evaluating the Safety Profile of Testosterone Therapy in Menopausal Women
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-27: Novoglan device for non-surgical treatment of phimosis – updated outcomes from the NOVOGLAN-01 clinical trial
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
IP22-28: Real-world evaluation of onset of action and efficacy of a novel Sildenafil oral suspension in men with erectile dysfunction
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
Federica Passarelli
IP22-29: Ursolic acid ameliorates cavernous nerve injury-related erectile dysfunction (CNI-ED) via promoting neuroregeneration and directly targeting NF-?B p65 signaling
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
KEFAN LI
IP22-30: Long-term testosterone replacement in females show no evidence of erythrocytosis and minimal side effect profile
Friday, May 15, 2026 3:30 PM to 5:30 PM
146C
Registered attendees
Filipe Tenorio
DirectorAndros Recife